Article
GLP-1 analogs restore inflammatory, mitochondrial and intercellular signaling networks in the <i> Snca <sup>G51D/G51D</sup> </i> knock-in mouse model of Parkinson’s disease
2026-05-19
Abstract excerpt
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a prolonged prodromal stage that culminates in motor deficits. Current PD therapies primarily alleviate symptoms, underscoring the need for disease-modifying strategies. Glucagon-like peptide-1 (GLP-1) analogs showed early promise as candidate disease modifiers, but recent clinical results have been inconsistent, and their mechanism of actio...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3bc8df5c-0b5f-5355-bba2-dc1f5287a1e4
- DOI
- 10.64898/2026.05.18.726024
